• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

UnitedHealthcare to cover Senseonics Eversense E3 CGM

June 5, 2023 By Sean Whooley

Marketing image Senseonics Eversense E3 Ascensia Diabetes Care
The Eversense E3 implantable CGM system. [Image from Ascensia/Senseonics]
Senseonics (NYSE:SENS) announced that UnitedHealthcare intends to begin providing coverage for its Eversense E3 CGM.

Coverage of the continuous glucose monitor for people with type 1 and insulin-requiring type 2 diabetes goes into effect on July 1, 2023. UnitedHealthcare, the largest health insurance company in the U.S., covers more than 45 million lives. Its offerings include health benefits, affordable coverage, a simplified healthcare experience and access to high-quality care.

Germantown, Maryland-based Senseonics designed its next-generation Eversense E3 CGM for long-term monitoring. The 180-day implantable CGM received FDA approval in February of last year.

Eversense E3 features a fully implantable third-generation sensor with sacrificial boronic acid (SBA) technology. The enhanced sensor longevity makes it what the company says is the longest-lasting CGM system. The sensor is fully implantable and requires just two sensor insertion and removal procedures per year.

Senseonics said the latest coverage adds to the existing payers who include Eversense in their CGM coverage policies. These policies now benefit approximately 300 million covered lives, enabling Senseonics’ global commercial partner Ascensia Diabetes Care to reach more people.

“The policy update from UnitedHealthcare marks an important milestone for increased access to long-term CGM for people with diabetes. With the addition of UnitedHealthcare, we are nearing all insured adults in the United States having access to the Eversense E3 CGM System,” said Tim Goodnow, president and CEO of Senseonics. “The Eversense E3 CGM system enables patients and health care providers to effectively manage diabetes for six months with sustained accuracy and a removable smart transmitter that provides vibratory alerts and comprehensive data regarding glucose values and trends.

“We are excited about the expanded opportunity to provide these differentiated benefits of Eversense to more people with diabetes in collaboration with our global commercial partner Ascensia Diabetes Care.”

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Implants, Patient Monitoring, Technology Tagged With: Senseonics, UnitedHealthcare

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS